Home Forums Other Specialities Therapeutics HYDROXYCHLOROQIUNE AND COVID- IN MILD TO MODERATE CASES-RCT

  • This topic has 0 replies, 1 voice, and was last updated 5 months ago by Anonymous.
Viewing 1 post (of 1 total)
  • Author
    Posts
  • #2700
    Anonymous
    Inactive

    ORIGINAL ARTICLE
    Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
    New England journal of Medicine -23rd July 2020

    BACKGROUND
    Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.
    METHODS

    We conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen.

    Patients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days. The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified intention-to-treat population (patients with a confirmed diagnosis of Covid-19). Safety was also assessed.

    RESULTS
    A total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis.
    As compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone ,or hydroxychloroquine plus azithromycin.

    Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent.

    CONCLUSIONS

    Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.

Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.